R&D channel feed – Endpoints News

R&D channel feed

Roche's I/O 2.0 dreams take a hit as TIGIT inhibitor fails PhIII

4 years ago

Touting a wad of cash in the wake of a clinical implosion, a small biotech reviews some limited options

4 years ago

With Bristol Myers in its sights, Pfizer declares itself the winner in the S1P drug race to come — but you’ll have to wait for proof

4 years ago

Inside the race to make psychedelics 'mainstream medicines'

4 years ago

Eli Lilly versus the 800-pound gorilla in atopic dermatitis? It may just have a shot — at 2nd place

4 years ago

Researchers point to a host-directed Covid-19 antiviral that could be combined with existing pandemic treatments

4 years ago

Slammed with fresh clinical failure, Biogen and Ionis discard early-stage ALS candidate

4 years ago

Amylyx shares routed on skeptical adcomm docs — but did the FDA leave an open door on unmet ALS need?

4 years ago

Big Pharma has skirted long Covid, but a pipeline of small biotechs is testing treatments for lingering symptoms

4 years ago

A biotech developing a synthetic biology Covid-19 vaccine comes up short in first data readout — and investors are fleeing

4 years ago

Bristol Myers' hope for a third Reblozyl OK delayed by three months

4 years ago

Jim Allison launches new institute aimed at speeding drug development and raising 'survival curve for all cancers'

4 years ago

As rivals stumble, Pfizer boasts of a second 'breakthrough' on PhIII RSV vaccine

4 years ago

AstraZeneca’s Imfinzi stumbles in cervical cancer, leaving Merck’s Keytruda dominant

4 years ago

A Bayer partner slims down, trimming R&D and enacting layoffs, to better focus on the pair's prostate cancer work

4 years ago

Moderna trades US baseball marketing for sumo wrestling ads in Japan

4 years ago

Pfizer yanks blood pressure meds amidst ongoing, industry-wide nitrosamine problems

4 years ago

Teva suffers setback on in-house asthma program as a PhII study is halted early due to futility

4 years ago

Vertex's R&D team maps a straight course to the FDA as it lays out pivotal search for another blockbuster

4 years ago

The first big test of Pfizer’s Arena buyout clears a PhIII in bid to catch up to Zeposia

4 years ago

Another small biotech watches its lead drug implode as its stock price tanks

4 years ago

Ahead of FDA committee to discuss new ALS drug, the jury remains out on how much benefit is enough for approval

4 years ago

PhIII failure triggers layoffs, spending cuts and warning of 'dissolution' for single-minded biotech

4 years ago

Big Pharma ad spending edges toward $7B with Sanofi, Regeneron and Novo Nordisk leading the way

4 years ago

First page Previous page 142 143 144145146 147 148 Next page Last page